APH vs NICE
Amphenol vs NICE Ltd. — AI-powered side-by-side comparison
| Metric | APH | NICE |
|---|
| AI Score |
61
|
65
|
| Price |
$161.34
|
$101.15
|
| P/E Ratio |
37.80×
|
14.36×
|
| ROE |
31.8%
|
15.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
38.5%
|
65.1%
|
| Debt / Equity |
1.21×
|
0.02×
|
| Dividend Yield |
0.6%
|
0.0%
|
| RSI (14) |
46.0
|
50.7
|
| Beta |
1.251
|
0.035
|
| Expected Upside |
+5.1%
|
+17.7%
|
AI Committee View
Current Innellis committee reasoning for APH versus NICE.
NICE leads by 4 points.
NICE scores 65/100 (Buy) versus APH at 61/100 (Buy).
APH Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 37.1% shows genuine earnings power backing the valuation — Value
- Revenue growing 54.2% YoY -- genuine top-line momentum — Growth
- EPS growing 59.4% YoY — Growth
Bear Case
- P/E of 40.4 is expensive by classic value standards — Value
- Price-to-book of 12.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
NICE Committee View
83% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 10.8 is inexpensive for the broad market — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- MACD histogram negative -- bearish momentum — Technical